{"publication_id":"faf58aa1-0279-46d8-a52f-a9e3f585c07c","traces":[{"claim_id":"claim_1","claim":"The direct receipts support a narrow working claim: The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk; Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.","candidate_sources":[{"study":"Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review","doi":"10.3390/ijms25084346","url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials","doi":"10.3390/ph14100991","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review","doi":"10.3390/ijms25084346","url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials","doi":"10.3390/ph14100991","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null}]},{"claim_id":"claim_3","claim":"Bounded signal: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.","candidate_sources":[{"study":"Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review","doi":"10.3390/ijms25084346","url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials","doi":"10.3390/ph14100991","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null}]},{"claim_id":"claim_4","claim":"`fact_id=139252` (`A_core`) — The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. doi=10.3390/ijms25084346","candidate_sources":[{"study":"Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review","doi":"10.3390/ijms25084346","url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials","doi":"10.3390/ph14100991","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null}]},{"claim_id":"claim_5","claim":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._","candidate_sources":[{"study":"Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review","doi":"10.3390/ijms25084346","url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials","doi":"10.3390/ph14100991","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null}]}]}